How APOE type and Alzheimer's changes affect individual brain cells

Project 4: Cross-species Dissection of Cellular Response to APOE Genotype and AD Pathology Using Single-cell Multi-omics

NIH-funded research J. David Gladstone Institutes · NIH-11166579

This project looks at how the APOE ε4 gene and Alzheimer’s-related proteins change single brain cells across species to guide better tests and treatments for people with or at risk for Alzheimer’s.

Quick facts

Grant typeP01 program project
Study typeNIH-funded research
Funding institutionJ. David Gladstone Institutes NIH-funded
Lab location1 site (San Francisco, United States)
Project IDNIH-11166579 on NIH RePORTER

What this research studies

Researchers will use single-cell multi-omics (including single-cell RNA and ATAC sequencing) to profile individual neurons and glia from animal models and human samples. They will compare effects of APOE genotypes, amyloid-beta, and tau pathology across brain regions to map cell-type specific responses. The team will link these cellular changes to prolonged neural network dysfunction and related signs like subclinical epileptiform activity. Findings will be integrated across species to highlight conserved pathways that could become targets for therapies or biomarkers.

Who could benefit from this research

Good fit: People with Alzheimer’s disease, individuals at risk because they carry the APOE ε4 variant, or people willing to donate brain tissue or other samples to research may be appropriate to contribute to this work.

Not a fit: People without Alzheimer’s pathology or APOE-related risk, and anyone seeking an immediate treatment, are unlikely to gain direct clinical benefit from this basic mechanistic research in the short term.

Why it matters

Potential benefit: If successful, this work could reveal specific cell types and molecular pathways to target for new therapies or early biomarkers for people with APOE ε4 or Alzheimer’s disease.

How similar studies have performed: Prior single-cell studies have identified cell-type changes in Alzheimer’s, but a large cross-species, APOE-focused single-cell multi-omics integration at this scale is relatively novel.

Where this research is happening

San Francisco, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.